OrthoPediatrics (NASDAQ:KIDS) Reaches New 12-Month Low Following Analyst Downgrade

OrthoPediatrics Corp. (NASDAQ:KIDS) reached a new 52-week low during mid-day trading on Monday after Truist Financial lowered their price target on the stock from $26.00 to $24.00. Truist Financial currently has a hold rating on the stock. OrthoPediatrics traded as low as $20.72 and last traded at $20.98, with a volume of 10700 shares traded. The stock had previously closed at $21.16.

KIDS has been the topic of a number of other research reports. Stifel Nicolaus dropped their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Lake Street Capital assumed coverage on shares of OrthoPediatrics in a research note on Monday, April 7th. They issued a “buy” rating and a $37.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.00.

Insider Buying and Selling

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company’s stock, valued at $7,934,193.30. The trade was a 2.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Fred Hite sold 6,443 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $160,172.98. Following the completion of the sale, the chief financial officer now owns 207,989 shares in the company, valued at $5,170,606.54. This represents a 3.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,732 shares of company stock worth $589,978. 31.80% of the stock is owned by insiders.

Institutional Trading of OrthoPediatrics

Institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. raised its stake in shares of OrthoPediatrics by 3.0% during the 4th quarter. Invesco Ltd. now owns 16,363 shares of the company’s stock worth $379,000 after acquiring an additional 469 shares in the last quarter. Northern Trust Corp grew its holdings in OrthoPediatrics by 0.3% in the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company’s stock worth $4,492,000 after purchasing an additional 644 shares during the last quarter. Rhumbline Advisers grew its holdings in OrthoPediatrics by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,411 shares of the company’s stock worth $612,000 after purchasing an additional 1,042 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of OrthoPediatrics by 125.1% during the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock worth $94,000 after purchasing an additional 1,929 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in shares of OrthoPediatrics during the 4th quarter valued at $48,000. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Price Performance

The stock has a 50-day moving average price of $24.14 and a two-hundred day moving average price of $24.72. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. The stock has a market cap of $512.46 million, a price-to-earnings ratio of -17.15 and a beta of 1.17.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. The company had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same period in the prior year, the company earned ($0.23) earnings per share. As a group, equities research analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.